Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade

被引:35
作者
Allen, SD
Rawale, SV
Whitacre, CC
Kaumaya, PTP
机构
[1] Ohio State Univ, Ohio State Biochem Program, Med Res Facil, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA
来源
JOURNAL OF PEPTIDE RESEARCH | 2005年 / 65卷 / 06期
关键词
CD28; CD40; CD40L; costimulation; costimulatory blockade; CTLA-4; experimental autoimmune encephalomyelitis; multiple sclerosis; peptide mimics;
D O I
10.1111/j.1399-3011.2005.00256.x
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cognate interactions between immune effector cells and antigen-presenting cells (APCs) govern immune responses. Specific signals occur between the T-cell receptor peptide and APCs and nonspecific signals between pairs of costimulatory molecules. Costimulation signals are required for full T-cell activation and are assumed to regulate T-cell responses as well as other aspects of the immune system. As new discoveries are made, it is becoming clear how important these costimulation interactions are for immune responses. Costimulation requirements for T-cell regulation have been extensively studied as a way to control many autoimmune diseases and downregulate inflammatory reactions. The CD28:B7 and the CD40:CD40L families of molecules are considered to be critical costimulatory molecules and have been studied extensively. Blocking the interaction between these molecules results in a state of immune unresponsiveness termed 'anergy'. Several different strategies for blockade of these interactions are explored including monoclonal antibodies (mAbs), Fab fragments, chimeric, and/or fusion proteins. We developed novel, immune-specific approaches that interfere with these interactions. Using experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis mediated by central nervous system (CNS)-specific T-cells, we developed a multi-targeted approach that utilizes peptides for blockade of costimulatory molecules. We designed blocking peptide mimics that retain the functional binding area of the parent protein while reducing the overall size and are thus capable of blocking signal transduction. In this paper, we review the role of costimulatory molecules in autoimmune diseases, two of the most well-studied costimulatory pathways (CD28/CTLA-4:B7 and CD40:CD40L), and the advantages of peptidomimetic approaches. We present data showing the ability of peptide mimics of costimulatory molecules to suppress autoimmune disease and propose a mechanism for disease suppression.
引用
收藏
页码:591 / 604
页数:14
相关论文
共 120 条
[71]   THE ROLE OF THE CD28 RECEPTOR DURING T-CELL RESPONSES TO ANTIGEN [J].
LINSLEY, PS ;
LEDBETTER, JA .
ANNUAL REVIEW OF IMMUNOLOGY, 1993, 11 :191-212
[72]   Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement [J].
Linsley, PS ;
Bradshaw, J ;
Greene, J ;
Peach, R ;
Bennett, KL ;
Mittler, RS .
IMMUNITY, 1996, 4 (06) :535-543
[73]   Costimulation blockade in the treatment of rheumatic diseases [J].
Liossis, SNC ;
Sfikakis, PP .
BIODRUGS, 2004, 18 (02) :95-102
[74]   Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival [J].
Lu, LN ;
Li, W ;
Fu, FM ;
Chambers, FG ;
Qian, SG ;
Fung, JJ ;
Thomson, AW .
TRANSPLANTATION, 1997, 64 (12) :1808-1815
[75]   Defining the clinical course of multiple sclerosis: Results of an international survey [J].
Lublin, FD ;
Reingold, SC .
NEUROLOGY, 1996, 46 (04) :907-911
[76]   Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis [J].
Lucchinetti, CF ;
Bruck, W ;
Rodriguez, M ;
Lassmann, H .
BRAIN PATHOLOGY, 1996, 6 (03) :259-274
[77]  
Marini JC, 1996, J IMMUNOL, V157, P3706
[78]  
Marino M, 1999, EUR J IMMUNOL, V29, P2560, DOI 10.1002/(SICI)1521-4141(199908)29:08<2560::AID-IMMU2560>3.0.CO
[79]  
2-X
[80]   Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand [J].
Markees, TG ;
Phillips, NE ;
Noelle, RJ ;
Shultz, LD ;
Mordes, JP ;
Greiner, DL ;
Rossini, AA .
TRANSPLANTATION, 1997, 64 (02) :329-335